高级检索
当前位置: 首页 > 详情页

Inhibition of STAT3 enhances UCP1 expression and mitochondrial function in brown adipocytes

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Tongren Hosp, Beijing Diabet Inst, Dept Endocrinol,Beijing Key Lab Diabet Res & Care, Beijing 100730, Peoples R China
出处:
ISSN:

关键词: Adipocytes differentiation Mature brown adipocytes JAK STAT3 pathway Nifuroxazide

摘要:
Extensive studies have shown that the increasing brown adipose tissue (BAT) mass/activity possesses a strong ability to prevent obesity and its related complications. The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signal pathway is known to play a role in adipocyte differentiation and development. However, its impact on thermogenic properties of mature brown adipocytes has not yet been clarified. Nifuroxazide (NFX), a potent inhibitor of STAT3, has received widespread attention due to its alternative anti-tumor and anti-inflammatory effects. Herein, we report that NFX induces lipolysis with subsequent downregulation of ACC alpha and FAS, while ATGL and pHSL levels are elevated in mature brown adipocytes. Furthermore, NFX treatment promotes the mitochondrial respiration of mature brown adipocytes, as evidenced by increased expression of thermogenic transcriptional factors and mitochondrial content. In addition, it also alleviates the IL6 and TNF alpha inhibition on brown thermogenic programming via suppressing the STAT3/NF-kappa B/IL-6 signaling pathway. In general, these findings suggest that the blockade of the JAK/STAT3 pathway by NFX has a prothermogenic effect on mature brown adipocytes which opens new perspectives for NFX repurposing and potential therapeutic route to counteract obesity and related metabolic disorders.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 3 区 药学
最新[2023]版:
大类 | 3 区 医学
小类 | 2 区 药学
JCR分区:
出版当年[2020]版:
Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Tongren Hosp, Beijing Diabet Inst, Dept Endocrinol,Beijing Key Lab Diabet Res & Care, Beijing 100730, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21173 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)